barusiban
Small moleculeexperimental
Barusiban is a non-peptide drug which is among the most potent and selective oxytocin receptor antagonists known. It was trialed by Ferring Pharmaceuticals as a treatment of preterm labor but failed to demonstrate effectiveness and was not pursued any further. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2003 (NCT00209326)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Oxytocin receptorANTAGONIST
OXTR antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@H](C)[C@@H]1NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)CCSCC[C@@H](C(=O)N(C)[C@H](CO)CCCN)NC(=O)[C@H](CC(N)=O)NC1=O- Mol. weight
- 830.07 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBarusiban ↗
- ChEMBLCHEMBL2218898 ↗
Also known as
- barusiban
- barusiban
- barusiban
- barusiban
- fe200440
- fe-200440
- fe-200440
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01723982 | Phase 2 | Nov 1, 2012 | Ferring |
| NCT01043120 | Phase 2 | Feb 1, 2010 | Ferring |
| NCT00587327 | Phase 2 | Nov 1, 2007 | Ferring |
| NCT00209326 | Phase 2 | Nov 1, 2003 | Ferring |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 4 | 4 | 1 | 2003 |
1 organizations
Page 1 / 1